Name | Sevirumab |
---|
Description | Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2]. |
---|---|
Related Catalog | |
Target |
EC50: 0.3 μg/mL (CMV)[1] |
In Vitro | Sevirumab (MSL-109) 扰乱 gH/gL 同型二聚体,而不是取消二聚。Sevirumab 可以将二聚体在足够的距离上分开,以减少荧光共振能量转移 (FRET),并最终阻止正常的 gH/gL 功能[2]。 |
References |
No Any Chemical & Physical Properties |